<DOC>
	<DOCNO>NCT00001333</DOCNO>
	<brief_summary>The purpose study determine qualitative quantitative toxicity intrathecal topotecan , topoisomerase I inhibitor , patient meningeal malignancy refractory conventional therapy ( radiation therapy chemotherapy ) .</brief_summary>
	<brief_title>Phase I Study Intrathecal Topotecan</brief_title>
	<detailed_description>The purpose study determine qualitative quantitative toxicity intrathecal topotecan , topoisomerase I inhibitor , patient meningeal malignancy refractory conventional therapy ( radiation therapy chemotherapy ) . A safe dose topotecan recommend intrathecal administration subsequent phase II study establish limited dosage escalation schedule . The CSF pharmacokinetics intrathecal topotecan also study . Topotecan administer intrathecally bi-weekly basis four six week , follow weekly administration 1 month , twice monthly administration four month monthly IT administration .</detailed_description>
	<mesh_term>Meningeal Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Leukemia , lymphoma , solid tumor overt meningeal involvement consider refractory conventional therapy . CSF leukemic cell count least 5 per cubic millimeter evidence blast cell cytospin cytology require leukemia lymphoma patient . Tumor cell cytospin cytology measurable meningeal disease CT MRI require patient solid tumor . No clinical evidence obstructive hydrocephalus compartmentalization CSF flow document indium111 technetium99DPTA flow study . PRIOR/CONCURRENT THERAPY : At least 1 week since CNS therapy . Biologic Therapy : Recovery toxic effect prior immunotherapy require . Chemotherapy : Recovery toxic effect prior chemotherapy require . No concomitant therapy treat meningeal malignancy ( intrathecal systemic ) . Concomitant chemotherapy control systemic disease bulk CNS disease allow except : Investigational agent . Agents penetrate CNS ( e.g. , highdose methotrexate , thiotepa , highdose cytarabine , fluorouracil , intravenous mercaptopurine ) . Agents know serious unpredictable CNS side effect . Endocrine Therapy : Not specify . Radiotherapy : Recovery toxic effect prior radiotherapy require . Patient eligible flow restore follow focal radiotherapy blockage site . Surgery : Not specify . PATIENT CHARACTERISTICS : Age : 3 ( old patient give consent enrol young , possible ) . Performance status : ECOG 02 . Life expectancy : At least 8 week . Hematopoietic : See Disease Characteristics . Hepatic : Bilirubin le 2.0 mg/dL , SGPT le 3 time normal . Renal : Creatinine le 1.5 mg/dL . Metabolic : Serum electrolyte ( include calcium phosphate ) normal . Other : No significant systemic illness ( e.g. , infection ) . Not pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>Intraventricular</keyword>
	<keyword>Meningeal Malignancy</keyword>
	<keyword>NSC 609699</keyword>
	<keyword>SKF 104864</keyword>
	<keyword>Topoisomerase 1</keyword>
</DOC>